Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:N05AX14
|
| gptkbp:CASNumber |
1620917-23-6
|
| gptkbp:developedBy |
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck |
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:hasMolecularFormula |
C17H17Cl2N3O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
D08170
|
| gptkbp:mechanismOfAction |
antagonist at serotonin 5-HT2A receptor
partial agonist at dopamine D2 receptor partial agonist at serotonin 5-HT1A receptor |
| gptkbp:PubChem_CID |
71585887
DB11732 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Brexpiprazole
|
| gptkbp:usedFor |
gptkb:major_depressive_disorder
schizophrenia |
| gptkbp:bfsParent |
gptkb:loratadine
|
| gptkbp:bfsLayer |
6
|